We serve Chemical Name:2,6-Difluoro-3-isopropoxyphenylboronic acid CAS:849062-04-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,6-Difluoro-3-isopropoxyphenylboronic acid
CAS.NO:849062-04-0
Synonyms:(2,6-difluoro-3-propan-2-yloxyphenyl)boronic acid
Molecular Formula:C9H11BF2O3
Molecular Weight:215.99000
HS Code:2931900090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:344.2ºC at 760 mmHg
Density:1.25g/cm3
Index of Refraction:1.481
PSA:49.69000
Exact Mass:216.07700
LogP:0.43180
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like (2,6-difluoro-3-propan-2-yloxyphenyl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2,6-difluoro-3-propan-2-yloxyphenyl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2,6-difluoro-3-propan-2-yloxyphenyl)boronic acid Use and application,(2,6-difluoro-3-propan-2-yloxyphenyl)boronic acid technical grade,usp/ep/jp grade.
Related News: Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. 2,6-Difluoro-3-isopropoxyphenylboronic acid manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2,6-Difluoro-3-isopropoxyphenylboronic acid supplier Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. 2,6-Difluoro-3-isopropoxyphenylboronic acid vendor Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. 2,6-Difluoro-3-isopropoxyphenylboronic acid factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.
